ArticleImmunologic research2013
Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab.
Article in Immunologic research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Association between serum visfatin levels and psoriasis and their correlation with disease severity: a meta-analysis.The Journal of international medical research · 2021Pooled it
- Increased serum resistin levels correlate with psoriasis: a meta-analysis.Lipids in health and disease · 2015Pooled it
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity.Life (Basel, Switzerland) · 2024Review
- Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality.Frontiers in immunology · 2022Article
- Serum Levels of Chemerin in Patients with Inflammatory Bowel Disease as an Indicator of Anti-TNF Treatment Efficacy.Journal of clinical medicine · 2021Article
- Management of psoriasis as a systemic disease: what is the evidence?The British journal of dermatology · 2020Review
- Analysis of serum chemerin concentrations in psoriatic patients in relation to metabolic abnormalities.Postepy dermatologii i alergologii · 2019Article
- Serum levels of adipokines and cytokines in psoriasis patients: a systematic review and meta-analysis.Oncotarget · 2018Article
- Single-Molecule Interactions of a Monoclonal Anti-DNA Antibody with DNA.BioNanoScience · 2017Article
- Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.Reviews in endocrine & metabolic disorders · 2016Review
- Recognition of oxidized albumin and thyroid antigens by psoriasis autoantibodies. A possible role of reactive-oxygen-species induced epitopes in chronic plaque psoriasis.Saudi medical journal · 2015Article
- Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis.Postepy dermatologii i alergologii · 2015Article
- Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics.PloS one · 2015Article
- Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.Immunologic research · 2013Article
- The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to analyse the prevalence of antinuclear antibodies in patients with psoriasis after treatment with infliximab and correlates the development of antibodies with both response to treatment and adipokines levels. Serum levels of ANA, anti-dsDNA, anti-histone, anti-nucleosome and anti-ENA antibodies at baseline after 2 and 12 months of treatment with infliximab were measured in 27 patients with psoriasis, as well as in 27 matched controls. Serum C-reactive protein (CRP), chemerin, visfatin and resistin were also assessed. The prevalence of ANA increased from 22 to 37% and 63% (p < 0.01) during treatment with infliximab, with a gradual progressive increase both in ANA titre and in percentage of ANA pattern. The prevalence of other antibodies also increased from 7 to 30% and 48% (p < 0.01) for anti-ds-DNA and from 7 to 26% and 37% for anti-nucleosome antibodies (p < 0.05), whereas the prevalence of anti-histone and anti-ENA antibodies was unchanged throughout the study period. Basal chemerin, resistin and CRP levels were higher in patients than in controls, and their levels progressively normalized during treatment (p < 0.01). Conversely, visfatin levels gradually increased (p < 0.01). ANA+ patients tended to show a faster decrease in PASI score, CRP and chemerin levels after 2 months, but the PASI score did not differ between ANA+ and ANA- patients at 12 months. A higher increase of visfatin was also found in ANA+ patients at 2 and 12 months. The antinuclear antibody response induced by infliximab was restricted to ANA, anti-dsDNA and anti-nucleosome antibodies. Patients who developed ANA positivity showed a faster clinical, inflammatory and immunological response to infliximab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.